Nitrates in the treatment of congestive heart failure

American Journal of Cardiology

Volumn 77, Issue 13, 1996, Pages C41-C51

  Elkayam, Uri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMLODIPINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; METHIONINE; MILRINONE; NITRATE; ORGANIC NITRATE; PHOSPHODIESTERASE INHIBITOR; PRAZOSIN;

ANGINA PECTORIS; CARDIOMYOPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERANCE; EXERCISE TOLERANCE; HEADACHE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MITRAL VALVE REGURGITATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; SURVIVAL; TRANSDERMAL DRUG ADMINISTRATION;

DRUG TOLERANCE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MITRAL VALVE INSUFFICIENCY; NITRATES;

EID: 0029882736     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00188-9     Document Type: Article

References (56)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
2. Packer M. The PRAISE trial (Prospective, Randomized. Amlodipine Survival Evaluation): background and main results. Presented at the American College of Cardiology annual meeting, New Orleans, March 1995.
3. Bennett BM, Schroder H, Hayward LD, Waldman SA, Murad F. Effect of in vitro organic nitrate tolerance on relaxation, cyclic GMP accumulation, and guanylate cyclase activation by glyceryl trinitrate and the enantiomers of isosorbide dinitrate. Circ Res 1988;63:693-701.
4. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of s-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
5. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
6. Mehra A, Shotan A, Ostrzega E, Hsueh W, Vasquez-Johnson J, Elkayam U. Potentiation of isosorbide dinitrate effects with N-acetylcysteine in patients with chronic heart failure. Circulation 1994;89:2595-2600.
7. Mehra A, Ostrzega E, Shotan A, Johnson JV, Elkayam U. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic heart failure already treated with captopril. Am J Cardiol 1992;70:1310-1314.
8. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987;76:577-584.
9. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
10. Dupuis J, Lalonde O, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-931.
11. Roth A, Kulick D, Freidenberger L, Hong R, Rahimtoola SH, Elkayam U. Early tolerance to hemodynamic effects of high-dose transdermal nitroglycerin in responders with severe chronic heart failure. J Am Coll Cardiol 1987;9:858-864.
12. Packer M, Medina N, Yushak M, Lee WH. Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study. Am Heart J 1985;109:1293.
13. Elkayam U. Roth A, Kumar A, Kulick D, McIntosh N, McKay CR, Rahimtoola SH. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. Am J Cardiol 1987;60:1106-1111.
14. Hecht HS, Karahalios SE, Schnugg SJ, Ormiston JA, Hopkins JM, Rose JG, Singh BN. Improvement in supine bicycle exercise performance in refractory congestive heart failure after isosorbide dinitrate: radionuclide and hemodynamic evaluation of acute effects. Am J Cardiol 1982;49:133-140.
15. Elkayam U. Nitrates in heart failure. Cardiol Clin 1994;12:73-85.
16. Boltwood CN, Tei MC, Wong M, Shah PM. Quantitative echocardiography of the mitral complex in dilated cardiomyopathy. The mechanism of functional mitral regurgitation. Circulation 1983;68:498.
17. Yoran C, Yellin EL, Becker RM, Gabbay S, Frater WM, Sonnenblick EH. Mechanism of reduction of mitral regurgitation with vasodilator therapy. Am J Cardiol 1979;43:773-777.
18. Mehra A, Shotan A, Kawanishi D, Ostrzega E, Vasquez-Johnson J, Elkayam U. Reduction in mitral valve regurgitant area secondary to left ventricular remodeling : a mechanism for improvement of mitral regurgitation mediated by vasodilator therapy. J Am Coll Cardiol 1993;21:352A.
19. Roth A, Shotan A, Elkayam U. A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation. Am Heart J 1993;125:155-163.
20. Leier CV, Huss P, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983;67:817-822.
21. Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 1980;69:559-560.
22. Cohn JN, Archibald D, Johnson G, et al. Effects of vasodilator therapy on peak oxygen consumption in heart failure: V-HeFT. (Abstr.) Circulation 1987;76(suppl IV):IV-443.
23. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al [V-HeFT]. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
24. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in the left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87(suppl VI):17-23.
25. Katz SD, Biasucci L, Sabba C, Strom J, Jondeau G, Golvano M, Solomon S, Nikolic SD, Forman R, LeJemtel TH. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992;19:918-925.
26. Schwarz M, Katz SD, Demopoulos L, Hirsch H, Yuen JL, Jondeau G, LeJemtel TH. Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure. Circulation 1994;89:1609-1614.
27. Sharpe N. Cardiac remodeling in congestive heart failure. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure. New York: Springer-Verlag, 1994:83-94.
28. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononirate. Circulation 1995;92:926-934.
29. Jugdutt BI. Intravenous nitroglycerin unloading in acute myocardial infarction. Am J Cardiol 1991;68(suppl):52D-63D.
30. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669.
31. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
32. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Iristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1542-1547.
33. Kulick D, Roth A, McIntosh N, Rahimtoola SH, Elkayam U. Resistance to isosorbide dinitrate in patients with chronic heart failure: incidence and attempt at hemodynamic prediction. J Am Coll Cardiol 1988;12:1023-1028.
34. Armstrong PW, Armstrong JA, Marks GS. Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive heart failure. Circulation 1980;62:160-166.
35. Elkayam U, Roth A, Henriquez B, Weber L, Tonnemacher D, Rahimtoola SH. Hemodynamic and hormonal effects of high-dose transdermal nitroglycerin in patients with chronic congestive heart failure. Am J Cardiol 1985;56:555-559.
36. Magrini F, Niarchos AP. Ineffectiveness of sublingual nitroglycerin in acute left ventricular failure in the presence of massive peripheral edema. Am J Cardiol 1980;45:841-847.
37. Packer M, Lee WH, Medina N, Gorlin R, Herman MV. Identification of patients with severe heart failure most likely to fail long-term therapy with converting-enzyme inhibitors. (Abstr.) J Am Coll Cardiol 1986;7:181A.
38. Packer M, Meller J, Medina N, Yushak M, Kessler P. Dose requirements of hydralazine in patients with severe chronic congestive heart failure. Am J Cardiol 1980;45:655-660.
39. Elkayam U, Roth A, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnson JV, Rahimtoola SH. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation 1991;84:2040-2048.
40. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-715.
41. Neuberg GW, Packer M, Medina N, et al. Reversal of nitroglycerin tolerance in patients with chronic heart failure by oral methionine. (Abstr.) Circulation 1989;80:II-213.
42. Levy WS, Katz RJ, Ruffalo RL, Leiboff RH, Wasserman AG. Potentiation of the hemodynamic effects of acutely administered nitroglycerin by methionine. Circulation 1988;78:640-645.
43. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;114:667-677.
44. May DC, Popma JJ, Black WH, Schaefer S, Lee HR, Levine BD, Hillis LD. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805-809.
45. Boesgard S, Aldershvile J, Poulsen HE, Loft S, Anderson ME, Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994;74:115-120.
46. Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983;68:1247-1253.
47. Dakak N, Makhoul N, Flugelman MY, Merdler A, Shehadeh H, Schneeweiss A, Halon DA, Lewis BS. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608-613.
48. Sharpe N, Coxon R, Webster M, Luke R. Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987;59:895-899.
49. Mehra A, Shotan A, Ostrzega E, Vasquez-Johnson J, Elkayam U. Escalating nitrate dose overcomes early attenuation of hemodynamic effect caused by nitrate tolerance in patients with heart failure. Am Heart J 1995;130:798-805.
50. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-39.
51. Gogia H, Mehra A, Parikh S, Raman M, Uppal JA, Johnson JV, Elkayam U. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-1580.
52. Unger P, Berkenboom G, Fontaine J. Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol 1993;21:478-483.
53. Munzel T, Kurz S, Rajagopalan S, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting vascular superoxide production. Circulation 1995;92:1-4.
54. Unger P, Vachiery JL, de Canniere D, Staroukine M, Berkenboom G. Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. Am Heart J 1994;128:557-563.
55. Franciosa JA, Weber KT, Levine TB, Kinasewitz GT, Janicki JS, West J, Henis MM, Cohn JN. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J 1982;104:587-594.
56. Fonarow GC, Chelimsky-Fallick C, Warner-Stevenson L, Luu M, Hamilton MA, Moriguchi JD, Tillisch JH, Walden JA, Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992;19:842-850.